LIFE: The European Patent Office intends to issue new Lifecare patent
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Bergen, Norway, November 8th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the European Patent Office (EPO) has reported its intent to grant Lifecare a new patent.
Lifecare will review the examining division’s comments to the patent application and respond to the EPO for their final review and granting of the patent. Lifecare expects the EPO to announce the granting of patent within the next 6 months.
The present application relates to chemistry compositions, in special active fluid compositions which may be used in glucose sensor systems, for example a glucose sensor which relies on osmotic pressure as sensing principle. The chemistry composition is a fundamental addition to Lifecare’s Sencell-technology and an important part for Lifecare’s further development and commercialization.
- In light of existing and granted patents for Lifecare’s sensor technology, this will strengthen our commercial position for accurate and continuous monitoring of glucose, for people with diabetes, says CEO Joacim Holter.
This new patent will strengthen Lifecare's technology protection until 2037.
- Existing continuous glucose measurement technologies are inconvenient, complicated, costly, and have limited lifetime. The Sencell system together with the active fluid composition according to the invention has advantageous effect on sensor lifetime, measurement response time, and measurement sensitivity, says Lifecare CSO, Prof. Dr. Dr. Med. Andreas Pfützner.